Skip to main content
SpringerLink
Log in

High-mobility group box 2 reflects exacerbated disease characteristics and poor prognosis in non-small cell lung cancer patients

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

High-mobility group box 2 (HMGB2) is considered as oncogene in non-small cell lung cancer (NSCLC), while its clinical implication is still unknown. This study aimed to explore the correlation of HMGB2 with clinicopathological characteristics and prognosis in NSCLC patients.

Methods

A total of 133 NSCLC patients who received radical excision were enrolled. HMGB2 expression in the tumor specimens and paired adjacent tissue specimens was determined by immunohistochemical assay (for protein expression) and reverse transcription quantitative polymerase chain reaction assay (for gene expression), respectively.

Results

HMGB2 protein expression was higher in tumor tissue compared with adjacent tissue, and it could distinguish tumor tissue from adjacent tissue (area under the curve (AUC): 0.775, 95%confidence interval (95%CI): 0.720–0.830). Meanwhile, tumor HMGB2 protein high expression correlated with lymph node (LYN) metastasis and advanced TNM stage. Additionally, tumor HMGB2 protein high expression associated with worse disease-free survival (DFS), while HMGB2 protein expression did not correlate with overall survival (OS). Besides, HMGB2 mRNA expression was raised in tumor tissue compared with adjacent tissue, and it had a good value in differentiating tumor tissue from adjacent tissue (AUC: 0.875, 95% CI: 0.834–0.915). Furthermore, tumor HMGB2 mRNA high expression correlated with higher Eastern Cooperative Oncology Group performance status score, LYN metastasis, and advanced TNM stage. Meanwhile, tumor HMGB2 mRNA high expression associated with shorter DFS and OS.

Conclusion

HMGB2 could be a biomarker that reflects disease features and prognosis of NSCLC, which is beneficial to improve clinical efficacy in NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Duma N, Santana-Davila R, Molina JR (2019) Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 94(8):1623–1640

    Article  CAS  Google Scholar 

  2. Goldstraw P, Ball D, Jett JR et al (2011) Non-small-cell lung cancer. Lancet 378(9804):1727–1740

    Article  Google Scholar 

  3. Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 377(9):849–861

    Article  CAS  Google Scholar 

  4. Field JK, Oudkerk M, Pedersen JH, Duffy SW (2013) Prospects for population screening and diagnosis of lung cancer. Lancet 382(9893):732–741

    Article  Google Scholar 

  5. Cheema PK, Rothenstein J, Melosky B et al (2019) Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol 26(1):37–42

    Article  CAS  Google Scholar 

  6. Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5(3):288–300

    Article  CAS  Google Scholar 

  7. Niu L, Yang W, Duan L et al (2020) Biological functions and theranostic potential of HMGB family members in human cancers. Ther Adv Med Oncol 12:1758835920970850

    Article  CAS  Google Scholar 

  8. Grasser KD, Launholt D, Grasser M (2007) High mobility group proteins of the plant HMGB family: dynamic chromatin modulators. Biochim Biophys Acta 1769(5–6):346–357

    Article  CAS  Google Scholar 

  9. Taniguchi N, Kawakami Y, Maruyama I, Lotz M (2018) HMGB proteins and arthritis. Hum Cell 31(1):1–9

    Article  CAS  Google Scholar 

  10. Kucirek M, Bagherpoor AJ, Jaros J et al (2019) HMGB2 is a negative regulator of telomerase activity in human embryonic stem and progenitor cells. FASEB J 33(12):14307–14324

    Article  CAS  Google Scholar 

  11. Kwon JH, Kim J, Park JY et al (2010) Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin Cancer Res 16(22):5511–5521

    Article  CAS  Google Scholar 

  12. Fu D, Li J, Wei J et al (2018) HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer. Cell Commun Signal 16(1):8

    Article  Google Scholar 

  13. Zhang P, Lu Y, Gao S (2019) High-mobility group box 2 promoted proliferation of cervical cancer cells by activating AKT signaling pathway. J Cell Biochem 120(10):17345–17353

    Article  CAS  Google Scholar 

  14. Li S, Yang J, Xia Y et al (2018) Long noncoding RNA NEAT1 promotes proliferation and Invasion via targeting miR-181a-5p in non-small cell lung cancer. Oncol Res 26(2):289–296

    Article  Google Scholar 

  15. Hu Z, Gu X, Zhong R, Zhong H (2018) Tumor-infiltrating CD45RO(+) memory cells correlate with favorable prognosis in patients with lung adenocarcinoma. J Thorac Dis 10(4):2089–2099

    Article  Google Scholar 

  16. Tian Y, Zhao K, Yuan L et al (2018) EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Cancer Biomark 23(2):291–300

    Article  CAS  Google Scholar 

  17. Pu J, Tan C, Shao Z et al (2020) Long noncoding RNA PART1 promotes hepatocellular carcinoma progression via targeting miR-590-3p/HMGB2 axis. Onco Targets Ther 13:9203–9211

    Article  CAS  Google Scholar 

  18. Cai X, Ding H, Liu Y et al (2017) Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of Warburg effect in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai) 49(2):119–127

    CAS  Google Scholar 

  19. Cui G, Cai F, Ding Z, Gao L (2019) HMGB2 promotes the malignancy of human gastric cancer and indicates poor survival outcome. Hum Pathol 84:133–141

    Article  CAS  Google Scholar 

  20. Yang S, Ye Z, Wang Z, Wang L (2020) High mobility group box 2 modulates the progression of osteosarcoma and is related with poor prognosis. Ann Transl Med 8(17):1082

    Article  CAS  Google Scholar 

  21. He ZH, Guo F, Hu XX et al (2020) Knockdown of HMGB2 inhibits proliferation and invasion of renal tumor cells via the p-38MAPK pathway. Eur Rev Med Pharmacol Sci 24(9):4729–4737

    PubMed  Google Scholar 

  22. Tang C, Yang Z, Chen D et al (2017) Downregulation of miR-130a promotes cell growth and epithelial to mesenchymal transition by activating HMGB2 in glioma. Int J Biochem Cell Biol 93:25–31

    Article  CAS  Google Scholar 

  23. Wu ZB, Cai L, Lin SJ et al (2013) High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance. Neuro Oncol 15(9):1264–1275

    Article  CAS  Google Scholar 

  24. Syed N, Chavan S, Sahasrabuddhe NA et al (2015) Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma. Proteomics 15(2–3):383–393

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Ning Lou and Tingting Zhu contributed equally to this work.

Authors and Affiliations

  1. Department of Pathology, Laigang Hospital Affiliated to Shandong First Medical University, No. 68 Xinxing Road, Jinan, 271126, China

    Ning Lou

  2. Department of Oncology, Laigang Hospital Affiliated to Shandong First Medical University, Jinan, China

    Tingting Zhu

  3. Department of Pathology, The Second People’s Hospital of Liaocheng, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University, Linqing, China

    Dongrui Qin & Jia Tian

  4. Department of Pathology, Baoding Maternal and Child Health Hospital, Baoding, Hebei, China

    Jiaqi Liu

Authors
  1. Ning Lou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tingting Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongrui Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jia Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiaqi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ning Lou.

Ethics declarations

Ethical approval

The Institutional Review Board approved the current study.

Competing interests

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lou, N., Zhu, T., Qin, D. et al. High-mobility group box 2 reflects exacerbated disease characteristics and poor prognosis in non-small cell lung cancer patients. Ir J Med Sci 191, 155–162 (2022). https://doi.org/10.1007/s11845-021-02549-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-021-02549-8

Keywords

Search

Navigation